Pseudo-rationale design of efficient TB vaccines: lesson from the mycobacterial 27-kDa lipoprotein.
To develop or improve acellular vaccines against tuberculosis, scientists are in quest for the most efficient Th1 antigens. Immunization of mice with the M. tuberculosis 27-kDa antigen resulted in a strong Th1 immune response as indicated by serum analysis, splenocyte proliferation and cytokines secretion profile. Unexpectedly, mice immunized with 27-kDa turned out to be more susceptible to mycobacterial challenge as we found significant increase in the splenic cfu count compared to control groups. Moreover, the protection provided by BCG or other mycobacterial antigens was completely abolished once the 27-kDa antigen was added to the vaccine preparations. Further analysis of 27-kDa revealed that this lipoprotein is a B-cell mitogen, a feature that is known to be linked to enhanced virulence of the pathogen. However, by using the non-acylated form, 27DeltaSP, we excluded the involvement of the mitogenicity of 27-kDa in its deleterious effect. Currently, there is no explanation to the fact that the 27-kDa interferes with the protective immunity of other mycobacterial antigens; however, it is clear that 27-kDa need to be excluded from any future vaccine preparations. Indeed, we developed a multivalent vaccine that consists of six other mycobacterial antigens: 85B, 38-kDa, ESAT-6, CFP21, Mtb8.4 and 16-kDa. Immunization of mice with these antigens emulsified in Ribi adjuvant system and supplemented with recombinant IFN-gamma, resulted in strong Th1 immune response and a high protection level that was comparable to that of BCG.
Hovav
Avi-Hai
AH
Division of Viral Pathogenesis, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Bercovier
Herve
H
D000276:Adjuvants, Immunologic; D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D049109:Cell Proliferation; D017358:Cell Wall Skeleton / Q000276:immunology; D003311:Cord Factors / Q000276:immunology; D004198:Disease Susceptibility; D005260:Female; D007111:Immunity, Cellular; D007113:Immunity, Innate; D007114:Immunization / Q000379:methods; D007371:Interferon-gamma / Q000276:immunology; D008050:Lipid A / Q000031:analogs & derivatives / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008934:Mitogens / Q000276:immunology; D009163:Mycobacterium bovis; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D011994:Recombinant Proteins / Q000096:biosynthesis; D013154:Spleen / Q000276:immunology; D018417:Th1 Cells / Q000276:immunology; D014376:Tuberculosis / Q000276:immunology* / Q000517:prevention & control; D032581:Tuberculosis Vaccines / Q000276:immunology*; D022282:Vaccines, Acellular / Q000276:immunology
C518582:27-kDa antigen, Mycobacterium tuberculosis; D000276:Adjuvants, Immunologic; D000942:Antigens, Bacterial; D017358:Cell Wall Skeleton; D003311:Cord Factors; D008050:Lipid A; D008934:Mitogens; D011994:Recombinant Proteins; C075897:Ribi adjuvant; D032581:Tuberculosis Vaccines; D022282:Vaccines, Acellular; D007371:Interferon-gamma